A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

NCT07593820 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Vall d'Hebron Institute of Oncology

Collaborators